Spectacle Prescribing in Early Childhood (SPEC)

项目总结 早期眼镜治疗对无症状幼儿中度屈光不正的益处 都是未知的。AAPOS眼镜处方指南，适用于3岁以下儿童 是以共识和临床经验为基础的，因为没有科学上的严谨 公布数据以供指导“。美国预防服务工作组于#年得出结论 2017年，没有足够的证据来评估视力筛查的好处平衡 3岁以下儿童，因为有关眼镜矫正的好处的数据 幼儿缺乏屈光不正。SPEC试验解决了这些重要的空白 侧重于评估景观的发展和视觉效益的文献 幼儿散光的治疗及与眼镜治疗相关的因素 这一年龄段的合规性。 SPEC是一项前瞻性试验，旨在确定是否处方和提供眼镜矫正 散光幼儿(12至24个月或24至36个月) 基于共识的处方指南可产生更好的发育和视觉效果 与36岁至40岁的散光儿童相比，他们得到了处方并提供了眼镜 月份。发育结果将使用贝利婴幼儿和儿童智力量表进行测量 幼儿发展，第三版。视力结果将使用弱视进行测量 治疗研究HOTV方案。眼镜治疗依从性将使用 戴在眼镜上的可穿戴传感器。 SPEC试验的结果将对筛查和治疗红斑狼疮具有重要意义。 年轻的散光儿童。这项研究将产生证据，告诉父母，儿科医生， 而眼科护理提供者如果给散光的幼儿配戴眼镜将会有好处 对其全球发展的影响，并将使临床医生能够以证据为基础，而不是 而不是基于共识的关于幼儿散光治疗的建议。这个 SPEC试验也是独一无二的，因为它包括眼镜治疗的客观措施 依从性，并将提供与眼镜治疗相关的因素方面急需的数据 学步儿童的依从性。

PROJECT SUMMARY The benefits of early spectacle treatment for moderate refractive error in asymptomatic toddlers are not known. AAPOS spectacle prescribing guidelines for children less than 3 years of age are based on consensus and clinical experience because “there are no scientifically rigorous published data for guidance”. The United States Preventive Services Task Force concluded in 2017 that there is insufficient evidence to assess the balance of benefits of vision screening for children less than 3 years of age because data on the benefits of spectacle correction for refractive error in toddlers are lacking. The SPEC Trial addresses these important gaps in the literature with a focus on assessing the developmental and visual benefits of spectacle treatment for astigmatism in toddlers, and the factors associated with spectacle treatment compliance in this age group. SPEC is a prospective trial to determine if prescribing and providing spectacle correction for astigmatic toddlers (at 12 to < 24 months or 24 to < 36 months of age) meeting current consensus based prescribing guidelines result in better developmental and visual outcome compared to astigmatic children who are prescribed and provided spectacles at age 36 to < 40 months. Developmental outcomes will be measured using the Bayley Scales of Infant and Toddler Development, 3rd Edition. Visual acuity outcome will be measured using the Amblyopia Treatment Study HOTV Protocol. Spectacle treatment compliance will be measured using a wearable sensor attached to the spectacles. The results of the SPEC Trial will have important implications for screening and treatment of young astigmatic children. This study will generate evidence to inform parents, pediatricians, and eye care providers if prescribing spectacles for astigmatic toddlers will have a beneficial effect on their global development, and will allow clinicians to make evidence-based, rather than consensus-based, recommendations regarding treatment of astigmatism in toddlers. The SPEC Trial is also unique in that it includes objective measures of spectacle treatment compliance, and will provide much needed data on factors associated with spectacle treatment compliance in toddlers.